

# UC San Diego

## UC San Diego Previously Published Works

### Title

Assessing Cognitive Functioning in People Living With HIV (PLWH): Factor Analytic Results From CHARTER and NNTC Cohorts.

### Permalink

<https://escholarship.org/uc/item/0br4q12f>

### Journal

J AIDS: Journal of Acquired Immune Deficiency Syndromes, 83(3)

### Authors

May, Pamela  
Heithoff, Abigail  
Wichman, Christopher  
[et al.](#)

### Publication Date

2020-03-01

### DOI

10.1097/QAI.0000000000002252

Peer reviewed



Published in final edited form as:

*J Acquir Immune Defic Syndr.* 2020 March 01; 83(3): 251–259. doi:10.1097/QAI.0000000000002252.

## Assessing Cognitive Functioning in People Living with HIV (PLWH): Factor Analytic Results from CHARTER and NNTC Cohorts

Pamela E. May, Ph.D.<sup>1</sup>, Abigail J. Heithoff, M.S.<sup>2</sup>, Christopher S. Wichman, Ph.D.<sup>3</sup>, Vaishali S. Phatak, Ph.D., ABPP<sup>1</sup>, David J. Moore, Ph.D.<sup>4</sup>, Robert K. Heaton, Ph.D.<sup>4</sup>, Howard S. Fox, M.D., Ph.D.<sup>2</sup>

<sup>1</sup>Department of Neurological Sciences, UNMC School of Medicine, Omaha, NE

<sup>2</sup>Department of Pharmacology and Experimental Neuroscience, UNMC School of Medicine, Omaha, NE

<sup>3</sup>Department of Biostatistics, UNMC School of Public Health, Omaha, NE

<sup>4</sup> Department of Psychiatry, UCSD School of Medicine, San Diego, CA

### Abstract

**Background**—Single summary scores, such as the Global Deficit Score (GDS), are often used to classify overall performance on neuropsychological batteries. The factor structure of test scores that underlie GDS in studies of persons living with HIV (PLWH) was assessed to determine if individual test scores loaded onto a unitary factor to summarize performance.

**Setting**—Secondary data analysis on baseline data of PLWH from National NeuroAIDS Tissue Consortium (NNTC) and CNS HIV Antiretroviral Therapy Effects Research (CHARTER) Study.

**Method**—Primary analyses included testing model structure and fit of neuropsychological test scores with confirmatory and exploratory factor analyses (CFAs and EFAs). Secondary analyses involved receiver operating characteristic curves, and associations with psychosocial and medical variables.

**Results**—Participants with confounds were excluded, leading to 798 (NNTC) and 1,222 (CHARTER) cases. When CFA models were structured to be consistent with theoretically-based cognitive domains, models did not fit adequately. Per EFAs, tests assessing speeded information processing, working memory, and executive functions loaded onto a single factor and explained the most variance in both cohorts. This factor tended to be associated with age, estimated premorbid ability, and aspects of substance use history. Its relation to age, in context of demographically-corrected neuropsychological scores, suggested accelerated aging.

**Conclusion**—Results indicate that individual neuropsychological tests did not load exactly onto expected domains, suggesting another framework for future analyses of cognitive domains. The

possibility of a new index, as well as its use to assess cognitive impairment in PLWH, is suggested for further diagnostic and prognostic purposes.

### Keywords

HIV; neuropsychology; HIV-associated Neurocognitive Disorder; factor analysis

---

### Introduction

Combination antiretroviral therapy (cART) has helped reduce morbidity and mortality associated with human immunodeficiency virus (HIV)<sup>1</sup>. In this context, cognitive impairment among people living with HIV (PLWH) has presented in milder forms as compared to pre-cART<sup>2,3</sup>. The profile of HIV-associated neurocognitive disorders (HAND) during the cART era has been reported to be diffuse<sup>4</sup> and variable, at times not only across cognitive domains, but also within cognitive domains<sup>5,6</sup>.

In the context of a comprehensive cognitive examination, different means to assess the presence of cognitive dysfunction or summarize cognitive findings in PLWH have been implemented<sup>7,8</sup>. When a *domain deficit score approach* is implemented, demographically-corrected scores are converted to ratings ranging from 0 to 5. Scores falling within normal ranges (T-score  $\geq 40$ ) are rated as 0, and as such, deficits ranging from 1 to 5 carry more weight in domain averages. In the deficit score approach, all test score ratings are averaged within each domain; scores  $>0.5$  suggest domain impairment, and two or more impaired domains are suggestive of overall cognitive impairment. Additionally, the *global deficit score* (GDS) is commonly implemented, which involves averaging deficit scores of all tests administered, with GDS  $\geq 0.5$  suggestive of global cognitive impairment. These different means of assessing dysfunction can be applied to the “Frascati” guidelines for diagnosing HAND developed by Antinori et al<sup>9</sup> (when data regarding comorbidities and daily functioning also are available).

Although it is worthy to examine the different strengths and weaknesses in cognitive profiles, often cognitive performance is summarized into a single, at times dichotomous score, such as when a GDS cut-off is used. A GDS  $\geq 0.5$  has been established to be suggestive of HAND<sup>8</sup>. GDS detects impairment, regardless of the pattern of results (as different neuropsychological patterns have been observed in PLWH<sup>5</sup>). However, whether performances on distinct tests should be averaged without significant a priori analysis (e.g., factor analysis) is questioned from a statistical perspective, particularly if less is known about the relative weighting and associations between test scores in a particular battery and how they may contribute to single, summary score.

In the current paper, our aims include examining the statistical structure of neuropsychological test performances in two cohorts of PLWH to assess whether performances load onto a unitary/global score, as well as detect which cognitive domains appear most sensitive to below normative cognitive performance in PLWH, in efforts to explore alternate means to identify facets of HIV-associated cognitive impairment. Prior literature has suggested that deficits in learning and executive functioning are the most predominant areas of weakness in PLWH (e.g., Heaton et al.<sup>2</sup>), with processing speed being

less prominent. However, other authors have suggested that speeded information processing may be most predictive of global cognitive functioning in PLWH, consistent with findings on effects of HIV on subcortical and white matter structures and factor analytic models<sup>10–13</sup>. We aimed to identify additional means to measure cognitive impairment based on factor analysis results. This examination will be completed using two large cohorts of PLWH, National NeuroAIDS Tissue Consortium (NNTC) and CNS HIV Anti-Retroviral Therapy Effects (CHARTER) Study.

## Method

### Participants

Baseline assessment data from adult PLWH from two longitudinal studies, NNTC and CHARTER, were examined consecutively. Baseline data from these cohorts were collected during the cART era. Please refer to NNTC<sup>14</sup> and CHARTER<sup>15</sup> for details regarding participant recruitment. NNTC recruited participants who had more severe HIV disease/greater risk of death (relative to CHARTER). If participants with global clinical ratings  $\geq 5$  on the cognitive battery (classified as impaired) were deemed to have cognitive impairment due to another condition(s) per clinical judgment (following Frascati guidelines), if the cause of impairment could not be determined, or if the clinician was unable to confidently assign a neurocognitive diagnosis, such participants were excluded. These exclusions resulted in final sample sizes of 798 and 1,222 for NNTC and CHARTER, respectively. Tables 1 and 2 provide demographic information regarding the samples used.

### Procedure and Measures

For CHARTER, cross-sectional data from the first neuropsychological visit were obtained from participants recruited from 2003 to 2007 (the complete CHARTER recruitment period). For NNTC, cross-sectional data from the first non-recruitment visit (following the screening visit) were pulled from participants who enrolled starting in 2000 until 2015. This period was chosen to maximize the number of participants analyzed from NNTC to compare to those used for CHARTER analyses. Refer to prior papers on CHARTER<sup>15</sup> and NNTC<sup>14</sup> for details regarding neuromedical examination and neuropsychological test batteries. Table 3 lists neuropsychological tests common to both CHARTER and NNTC.

For the purposes of factor analysis, tests were presumed to be specific to seven cognitive domains as outlined in Woods et al.<sup>14</sup> and additional analyses by CHARTER group (see domains in Table 3). Factor analyses on neuropsychological tests were completed on normalized scaled scores (mean=10; standard deviation=3) that were not demographically-corrected and therefore, reflect absolute levels of performance. Additional analyses were completed on demographically-corrected T-scores adjusting for effects of age, education, sex, and race/ethnicity (where available), as generated from Heaton, Norman et al.<sup>16</sup>, and normative data from individual test developers.

## Statistical Analysis

Factor analyses were conducted with SAS. Receiver operating characteristic (ROC) curve analyses were conducted in PRISM (version 7.0e). Univariate and regression analyses were conducted in SPSS (version 25).

Primary analyses included factor analysis. Listwise deletion was implemented for factor analyses. Analyses were completed in CHARTER first, followed by NNTC, to serve as training and testing datasets, respectively. Confirmatory factor analysis (CFA) was first used to test the structure and fit of neuropsychological domains as previously specified in literature. Exploratory factor analysis (EFA) were next utilized to identify the factor structure of neuropsychological test scores, from a data-driven approach. Serial CFAs, as influenced by EFA structural models, were then tested to identify models with the best fit in CHARTER and then NNTC. The following model statistics and threshold values were used to evaluate acceptable model fit per literature guidelines<sup>17–19</sup>: Bentler's Comparative Fit Index (BCFI; values>.95), Root Mean Square Error of Approximation (RMSEA; values<.07), Bentler-Bonnett Normative Fit Index (BBNFI; values>.95), and Standardized Root Means Square Residual (SRMR; values<.08).

Secondary analyses were conducted to compare an identified index from these factor analyses to other classification schemes (Frascati/clinical ratings and GDS), as well as examine variables that account for variance in this index. Variables of interest included psychosocial history (i.e., age, sex, race/ethnicity, years of education, estimated premorbid ability, and Beck Depression Inventory-2<sup>nd</sup> edition score), HIV-related factors (i.e., nadir CD4 [cells/ $\mu$ L; square-root transformed to normalize distribution], current CD4 [cells/ $\mu$ L; square-root transformed to normalize distribution], and estimated years/duration of HIV), medical history (i.e., lifetime history of hypertension, hyperlipidemia, diabetes, high cholesterol, viral hepatitis, seizure, and head injury), and substance use (i.e., lifetime history of alcohol, cocaine, methamphetamine, and opiate abuse/dependence).

## Results

Cohort sample characteristics were compared with t-tests and chi-square analyses (see Tables 1 and 2). There were significant differences between cohorts with respect to age, race/ethnicity, depressive symptoms, estimated HIV duration, current CD4, nadir CD4, HIV treatment, hemoglobin, lifetime history of multiple medical problems (i.e., viral hepatitis, hypertension, and hyperlipidemia), and lifetime history of substance use (cocaine, methamphetamine, and alcohol), with NNTC broadly reflecting an older and health-compromised sample relative to CHARTER (as expected). The CHARTER cohort appeared to have a greater proportion of participants with positive substance use histories, relative to NNTC. Zero-order correlations for neuropsychological scaled scores within each cohort are reported in Supplemental Tables 1 and 2.

### Primary Analyses and Results

**Factor Confirmation/Development**—A series of factor analyses was conducted on neuropsychological scaled scores to assess if test scores loaded onto seven domains, as

previously proposed (see Table 3). Factor analyses were completed on CHARTER first, as the training dataset, and on NNTC second, as the testing dataset. With listwise deletion, only 3% of the sample fell out of the analyses for CHARTER, while 23% of the sample fell out for the analyses for NNTC.

Utilizing the 7-domain structure resulted in CFAs with less than adequate fit in CHARTER (RMSEA = .10; BCFI = .92; BBNFI = .91; SRMR = .04; see Supplemental Figure 1 for structure and standardized factor loadings). We attempted to improve model fit by including an exogenous, latent cognitive factor (i.e., overarching factor that is not caused by other factors; borrowing the concept of a global deficit score). This model did not converge.

In this context, the next step was to explore the structure of data, from a data-driven approach. As such, an oblique exploratory factor analysis (EFA) on the correlation matrix for all neuropsychological test scaled scores was conducted in CHARTER (see Supplemental Figure 2 for model structure and standardized factor loadings). This EFA model identified six factors and multiple inter-factor correlations. The first identified factor (including test scores representing speeded information processing, working memory, and executive functioning), explained most of the total variation (for CHARTER: 46% of total variance). The remaining factors consisted of measures from a single test (Grooved Pegboard, HVLt-R, BVMT-R, or WCST) and/or with common method variance (two verbal fluency measures).

Subsequently, the CFA model was modified to incorporate the six-factor structure as suggested by EFA results, without permitting factors to correlate. This model was not interpretable per model warnings. Adding an exogenous, latent cognitive factor, in addition to this six-factor structure improved overall model fit to acceptable standards for CHARTER (RMSEA = .07, BCFI = .96; BBNFI = .95; SRMR = .04). However, when this model was applied to NNTC, it was not interpretable per model warnings.

Alterations to models continued, to determine if a similar structure would be acceptable in both cohorts. Model fit was good for CHARTER (RMSEA = .07, BCFI = .97; BBNFI = .97; SRMR = .03) and then NNTC (RMSEA = .07, BCFI = .96, BBNFI = .95, SRMR = .04) when there were four-factors, without verbal fluency or WCST scores (see Figure 1A,B for structure and standardized factor loadings). Fit indices for these models remained largely the same with the addition of an exogenous, latent general cognitive factor for both cohorts. The first identified factor (including speeded processing, working memory, and executive function measures) accounted for 75% of total variance in CHARTER and 65% of total variance in NNTC. Of note, test scores that comprised this first factor were robustly stable across models, in both cohorts.

**Secondary Analyses and Results**—Secondary analyses were completed to assess the utility of an index score generated from the initial factor in EFAs and best-fitting CFAs across cohorts, as a metric for assessing cognitive impairment in PLWH. Given the nature of the tests that comprise Factor 1, this factor was denoted as the “Cognitive Efficiency Factor” (CEF). Demographically corrected T-scores were used in these secondary analyses, as better reflective of variance of performance from normative expectations.

CEF was first calculated as the arithmetic average of T-scores of the six neuropsychological tests that comprised the initial EFA and final CFA models (i.e., WAIS-III Digit Symbol, WAIS-III Symbol Search, WAIS-III Letter Number Sequencing, Trail Making Test – Part A, Trail Making Test – Part B, Paced Auditory Serial Addition Task – first channel only). A minimum of four of six scores was required for CEF calculation. Although individual loading values onto this initial factor/CEF were not identical, their relative magnitudes/weightings were similar. No significant discrepancy between arithmetic mean vs. a weighted mean was found in either cohort. In both cohorts, CEF average T-scores showed a good fit to a Gaussian distribution (see Figure 2A).

Since domain deficit scores (DDS) show great utility in assessment of impairment, DDS was also calculated for CEF, for comparison. Domain deficit scores were generated by converting T-scores for individual neuropsychological tests that comprise CEF to 0 to 5 ratings. These ratings were then averaged by total number of tests (six) to calculate DDS. As expected, DDS was skewed towards lower values (Figure 2B).

Both average T-scores and DDS were statistically capable of distinguishing HAND levels (Figures 2C,D). While CEF was not developed to identify all of the deficits that can comprise HAND, we next compared the classification accuracy of CEF (either as average T-scores or DDS) with GDS in distinguishing individuals considered neuropsychologically normal versus individuals diagnosed with HAND by the clinical ratings/Frascati approach. Receiver operator characteristic (ROC) curve analyses indicated that neither method was as good as GDS in diagnosing impairment as a dichotomous outcome (Figure 2E).

A cut-off value for CEF average T-score was defined for practical purposes. As normative values were not available, we examined CEF average T-score values from those considered neuropsychologically normal in the NNTC and CHARTER cohorts. These values followed a normal distribution (Figure 3F). We defined 1.5 standard deviations (SD) below the mean as significant impairment. As such, CEF average T-scores < 41.7 were considered impaired and average T-scores  $\geq$  41.7 were normal. Similar to other definitions, we used a cutoff of DDS > 0.5 for impairment (Figure 3F).

**Predictors of CEF values:** Exploratory independent sample t-tests and chi-square tests were conducted to find predictors of CEF average T-score and DDS (by aforementioned cut-offs). To control for multiple comparisons in CHARTER, we used the Benjamini-Hochberg procedure by dependent variable. With this correction, only adjusted *p*-values < .05 were considered statistically significant.

***CHARTER analyses:*** With respect to impairment frequencies, 19.9% of the CHARTER sample had CEF average T-score < 41.7, and 22.4% had CEF DDS > 0.5. Independent samples t-tests revealed that impaired CEF average T-score was associated with greater age, lower nadir CD4, lower hemoglobin, greater estimated duration of HIV, and lower premorbid ability. Chi-square analyses with categorical covariates revealed that CEF average T-score was independently associated with lifetime history of cocaine and methamphetamine abuse/dependence; direction of findings unexpectedly suggested that individuals with such substance use histories were more likely to have normal CEF, than not. Results also revealed



that individuals with impaired CEF average T-score had a higher proportion of positive diabetes, hyperlipidemia, and high cholesterol lifetime histories, than those with normal CEF T-score. Supplemental Tables 3 and 4 list results by CEF T-score.

Additional independent samples t-tests revealed detectable associations between CEF DDS, age, years of education, premorbid ability, HIV duration, and nadir CD4, with greater age, higher years of education, lower premorbid ability, longer HIV duration, and lower nadir CD4 associated with impaired CEF DDS. Chi-square analyses revealed that CEF DDS was independently associated with lifetime history of cocaine, methamphetamine, and alcohol abuse/dependence; with results suggesting that individuals with such substance use history were more likely to have normal CEF DDS, than not. Results also revealed that individuals with impaired CEF DDS had a higher proportion of positive diabetes, hyperlipidemia, and high cholesterol lifetime histories, than those with normal CEF DDS. Supplemental Tables 5 and 6 list results by CEF DDS.

Based on these results, multiple regression was used to assess the relative value of age, premorbid ability, nadir CD4, estimated duration of HIV, hemoglobin, lifetime histories of cocaine, and methamphetamine abuse/dependence, hyperlipidemia, high cholesterol, and diabetes in predicting CEF average T-score (as a continuous variable). The model revealed a collective, significant effect of these variables on CEF average T-score,  $F(10, 1,104) = 30.61$ ,  $p < .001$ ). Review of standardized coefficients revealed that only age ( $\beta = -.33$ ), premorbid ability ( $\beta = .23$ ), hemoglobin ( $\beta = .06$ ), and lifetime history of diagnosed cocaine abuse/dependence ( $\beta = .17$ ) remained as significant predictors of CEF average T-score ( $p$ -values  $< .05$ ).

Further, multiple regression was used to assess the relative value of age, years of education, premorbid ability, estimated duration of HIV, nadir CD4, lifetime histories of cocaine, methamphetamine, and alcohol abuse/dependence, hyperlipidemia, high cholesterol, and diabetes in predicting CEF DDS (as a continuous variable). The model revealed a collective significant effect of these variables on CEF DDS,  $F(11, 1,111) = 16.39$ ,  $p < .001$ ). Review of standardized coefficients revealed that only age ( $\beta = .17$ ), years of education ( $\beta = .18$ ), premorbid ability ( $\beta = -.24$ ), estimated duration of HIV ( $\beta = .06$ ), and lifetime history of diagnosed cocaine abuse/dependence ( $\beta = -.14$ ) continued to have detectable associations with CEF DDS ( $p$ 's  $< .05$ ).

**NNTC analyses:** Analyses were completed on a sample of 766 NNTC participants. CEF value could not be calculated for 32 participants, as they had fewer than four values for tests comprising CEF. With respect to impairment frequencies, 29.2% had CEF average T-score  $< 41.67$ , and 28.9% had CEF DDS  $> 0.5$ . Where possible, analyses were completed on variables similar to those in CHARTER. The Benjamini-Hochberg procedure was used to control for multiple comparisons. With this correction, only adjusted  $p$ -values  $< .05$  were considered statistically significant.

Independent samples t-tests did not reveal any significant associations with CEF average T-score ( $p$ 's  $> .001$ ). Chi-square analyses with categorical covariates revealed that CEF average T-score was only dependent on race/ethnicity, likely secondary to relatively higher



proportions of Hispanic and “other” race/ethnicity categories having CEF average T-score < 41.7, relative to participants in Caucasian/White and African American/Black categories. Supplemental Tables 7 and 8 report results by CEF average T-score.

Similarly, independent samples t-tests did not reveal significant associations with CEF DDS (all  $p$ 's > .001). Chi-square analyses with categorical covariates revealed that CEF DDS was dependent on race/ethnicity, with the same pattern of results previously demonstrated with CEF average T-score. Supplemental Tables 9 and 10 report results by CEF DDS.

## Discussion

Findings from two samples of PLWH suggested that neuropsychological variables did not readily load onto a single unitary factor representative of global cognitive functioning, without further data reduction. When neuropsychological data were reduced, generated models demonstrated adequate fit when a global cognitive functioning score was present or absent. Further, results indicated that individual neuropsychological test scores did not load onto theoretically-defined cognitive domains as expected, or previously reported in literature. Attention, working memory, and speeded information processing loaded onto a common factor, and learning and recall scores loaded onto similar factors, by modality (verbal versus visual). Final models for CHARTER and NNTC indicated that tests assessing speeded information processing (i.e., WAIS-III Symbol Search, Digit Symbol, Trails A), working memory (i.e., WAIS-III Letter-Number Sequencing and PASAT), and cognitive set-shifting (i.e., Trails B) explained most of the total variation in cognitive functioning in these samples of PLWH (46–48% per EFAs and 65–76% per CFAs). We refer to this particular factor as “cognitive efficiency” factor/CEF). We explored the characteristics of CEF and its possible utility as an alternate cognitive index score based on factor analysis, in PLWH.

When examining variables that may account for CEF, a few consistent predictors of CEF emerged. In CHARTER, participant age, premorbid ability, nadir CD4, estimated HIV duration, hemoglobin, and lifetime histories of diabetes, high cholesterol, hyperlipidemia, cocaine abuse/dependence, and methamphetamine abuse/dependence were associated with CEF average T-score. The same variables were associated with CEF DDS, with the exception of hemoglobin. Further, there were unique associations between years of education and lifetime history of alcohol abuse/dependence with CEF DDS. It was expected that age would inversely predict CEF, as frontal and subcortical areas are vulnerable to both HIV and aging effects, leading to decline in speeded functions<sup>20</sup>. Current findings may suggest accelerated cognitive aging, as the demographically-corrected T-scores used to calculate CEF had already corrected for “normal” aging. Accelerated or advanced aging is consistent with other findings in HIV-infected subjects<sup>21–24</sup>. It was also expected that normal CEF would be positively associated with level of premorbid ability or cognitive reserve. The direction of CEF's associations with nadir CD4 and estimated HIV duration are consistent with the literature, as lower nadir CD4 and longer HIV disease duration have been associated with greater cerebral atrophy<sup>25</sup> and neuropsychological impairment<sup>26,27</sup>. With respect to hemoglobin, low levels/anemia have been found to be associated with lower GDS<sup>28</sup>, consistent with our findings. Further, the development of cerebrovascular risk factors, such as diabetes and hyperlipidemia<sup>29</sup>, have been speculated to reflect an indirect

effect of HIV infection/treatment, and have been shown to be risk factors for cognitive impairment in HIV<sup>30,31</sup>. However, there does not appear to be a clear explanation for the positive associations of cocaine, methamphetamine, and alcohol abuse/dependence history with CEF. Of note, participants with these positive substance use histories tended to use other substances as well, making conclusions related to any one particular substance use difficult. Recent literature reviews on the topic of cognition and cocaine<sup>32</sup> suggest that cocaine use does not tend to lead to gross cognitive impairment, and differences in performance between users and non-users on select cognitive tests are relatively small, highlighting that there may not be clinically significant changes in cognition related to using these substances, in general. Interestingly, when examining significant predictors of CEF average T-score collectively, only a few variables remained significant, including age, premorbid ability, hemoglobin, and history of cocaine abuse/dependence, with age accounting for the most variance. Contrarily, results differed slightly when collectively examining significant predictors of CEF DDS; in this context, premorbid ability, years of education, age, estimated HIV duration and history of cocaine abuse/dependence were the only variables that remained statistically significant, with premorbid ability accounting for the most variance. Both sets of results suggest that psychosocial variables, including age and premorbid ability, may hold more weight than variables specific to the HIV disease process (e.g., nadir CD4 and estimated HIV duration) and other variables reflective of contributing medical histories, when examining neurocognitive impairment in PLWH.

In NNTC, race/ethnicity was the only covariate significantly associated with CEF, with participants identified as Hispanic and “Other” exhibiting higher proportions of impaired CEF. There were relatively smaller sample sizes for Hispanic and “Other” groups. The effect of having less representative normative data for these groups, relative to those available for Caucasians and African Americans, cannot be ruled out. Further, we also cannot rule out the impact of cultural bias and other psychosocial factors, including language, on these results. However, another CHARTER study revealed that Hispanics were more likely to decline neurocognitively over on average a three-year follow-up<sup>33</sup>. This association with Hispanic ethnicity was not anticipated by the respective authors, yet was posited to be in part secondary to reduced access to healthcare, relative to non-Hispanic whites.

The finding that “cognitive efficiency” is a prominent cognitive factor across cohorts is consistent with select literature on cognition<sup>13,2,34</sup> and neuroimaging<sup>10,11</sup> in PLWH. Overall, there tends to be a mild frontal-subcortical profile characteristic in PLWH, although this profile has been previously considered to be “spotty” without great consistency<sup>15</sup> or uniform underlying neuropathology<sup>35</sup>. The current analyses touch on both points, as multiple cognitive factors (i.e., “cognitive efficiency,” learning/memory, and fine motor dexterity) derived from our final CFA analyses were found to be predictive of overall cognitive functioning in two cohorts of PLWH, yet “cognitive efficiency” appeared to account for the greatest variance.

Limitations of the analyses include lack of a gold-standard for identifying cognitive impairment in PLWH (outside of neuropsychological test performance) as well as lack of a control/normal group for comparison. Results from CFAs may reflect, in part, shared methods variance. In addition, CFA model results for NNTC may be biased as 23% of the

sample was removed secondary to listwise deletion. Furthermore, neuropsychological variables were limited to those available in research test batteries. Of note, these test batteries included slightly more measures that were speeded in nature, than other cognitive tasks. Lastly, although “cognitive efficiency” appears to be an important component of a comprehensive test battery, we do not recommend or imply that it replace a comprehensive battery.

The current analyses identified an alternate cognitive index (measurable by average T-score or DDS) that warrants further investigation, with respect to distinguishing PLWH who are cognitively intact versus those with impairment. We intend to isolate a subpopulation who may follow a unique trajectory, infection outcome, and/or respond differentially to treatment regimens. The proposed index may be relatively easy to implement in research and clinical practice. Future directions include investigating predictors of “cognitive efficiency” as well as identifying how the HIV disease process is associated with changes in “cognitive efficiency” over time. The ultimate goals are to assess if cognitive efficiency can serve as a practical marker of cognitive prognosis in HIV, help improve diagnostic accuracy of cognitive impairment among PLWH, and to find a measure that can be potentially valuable for preventative or treatment trials.

## Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

## Acknowledgments

The authors gratefully appreciate and acknowledge the investigators and staff associated with NNTC and CHARTER, as well as the participants who partook in these studies. Support for the NNTC is provided by the National Institutes of Health (NIH) under Award Numbers U24MH100925 U24MH100928, U24MH100929, U24MH100930, and U24MH100931. The CHARTER studies were supported under NIH contracts N01 MH22005, HHSN271201000030C, and HHS-N-271-2010-00036C.

The information in this manuscript and the manuscript itself have never been published either electronically or in print. Preliminary results were presented at the annual conference of American Academy of Clinical Neuropsychology, in San Diego, CA (June 2018).

### Conflicts of Interest and Source of Funding

No conflicts of interest were declared by the authors. This work was supported by the National Institutes of Health (NIH) under Award Number U24MH100925 to HSF and U24MH100928 to DJM. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH, CHARTER, or NNTC.


## References

1. Cihlar T, Fordyce M. Current status and prospects of HIV treatment. *Current opinion in virology*. 2016;18:50–56. [PubMed: 27023283]
2. Heaton RK, Franklin DR, Ellis RJ, et al. HIV-associated neurocognitive disorders before and during the era of combination antiretroviral therapy: differences in rates, nature, and predictors. *J Neurovirol*. 2011;17(1):3–16. [PubMed: 21174240]
3. Cysique LA, Brew BJ. Neuropsychological functioning and antiretroviral treatment in HIV/AIDS: a review. *Neuropsychology review*. 2009;19(2):169–185. [PubMed: 19424802]
4. Woods SP, Moore DJ, Weber E, Grant I. Cognitive neuropsychology of HIV-associated neurocognitive disorders. *Neuropsychology review*. 2009;19(2):152–168. [PubMed: 19462243]


5. Dawes S, Suarez P, Casey CY, et al. Variable patterns of neuropsychological performance in HIV-1 infection. *J Clin Exp Neuropsychol.* 2008;30(6):613–626. [PubMed: 18608689]
6. Heaton RK, Grant I, Butters N, et al. The HNRC 500--neuropsychology of HIV infection at different disease stages. HIV Neurobehavioral Research Center. *Journal of the International Neuropsychological Society : JINS.* 1995;1(3):231–251. [PubMed: 9375218]
7. Devlin KN, Giovannetti T. Heterogeneity of Neuropsychological Impairment in HIV Infection: Contributions from Mild Cognitive Impairment. *Neuropsychology review.* 2017;27(2):101–123. [PubMed: 28536861]
8. Blackstone K, Moore DJ, Franklin DR, et al. Defining neurocognitive impairment in HIV: deficit scores versus clinical ratings. *Clin Neuropsychol.* 2012;26(6):894–908. [PubMed: 22708483]
9. Antinori A, Arendt G, Becker JT, et al. Updated research nosology for HIV-associated neurocognitive disorders. *Neurology.* 2007;69(18):1789–1799. [PubMed: 17914061]
10. Becker JT, Sanders J, Madsen SK, et al. Subcortical brain atrophy persists even in HAART-regulated HIV disease. *Brain imaging and behavior.* 2011;5(2):77–85. [PubMed: 21264551]
11. Jernigan TL, Archibald SL, Fennema-Notestine C, et al. Clinical factors related to brain structure in HIV: the CHARTER study. 2011;17(3):248.
12. Ragin AB, Wu Y, Storey P, Cohen BA, Edelman RR, Epstein LGJJoN. Diffusion tensor imaging of subcortical brain injury in patients infected with human immunodeficiency virus. 2005;11(3):292–298.
13. Fellows RP, Byrd DA, Morgello S. Effects of information processing speed on learning, memory, and executive functioning in people living with HIV/AIDS. *J Clin Exp Neuropsychol.* 2014;36(8):806–817. [PubMed: 25111120]
14. Woods SP, Rippeth JD, Frol AB, et al. Interrater reliability of clinical ratings and neurocognitive diagnoses in HIV. *J Clin Exp Neuropsychol.* 2004;26(6):759–778. [PubMed: 15370374]
15. Heaton RK, Clifford DB, Franklin DR, Jr., et al. HIV-associated neurocognitive disorders persist in the era of potent antiretroviral therapy: CHARTER Study. *Neurology.* 2010;75(23):2087–2096. [PubMed: 21135382]
16. Norman MA, Moore DJ, Taylor M, et al. Demographically corrected norms for African Americans and Caucasians on the Hopkins Verbal Learning Test–Revised, Brief Visuospatial Memory Test–Revised, Stroop Color and Word Test, and Wisconsin Card Sorting Test 64-Card Version. *Journal of Clinical and Experimental Neuropsychology.* 2011;33(7):793–804. [PubMed: 21547817]
17. Bollen KAL J Scott Testing Structural Equation Models. Newbury Park, CA: Sage; 1993.
18. Bollen KA. *Structural Equations with Latent Variables.* New York, NY: Wiley; 1989.
19. Hooper D, Coughlan J, Mullen M *Structural Equation Modelling: Guidelines for Determining Model Fit.* 2008 Dublin Institute of Technology 2008.
20. Kerchner GA, Racine CA, Hale S, et al. Cognitive processing speed in older adults: relationship with white matter integrity. *PloS one.* 2012;7(11):e50425–e50425. [PubMed: 23185621]
21. Goodkin K, Miller EN, Cox C, et al. Effect of ageing on neurocognitive function by stage of HIV infection: evidence from the Multicenter AIDS Cohort Study. *The lancet HIV.* 2017;4(9):e411–e422. [PubMed: 28716545]
22. Sheppard DP, Iudicello JE, Morgan EE, et al. Accelerated and accentuated neurocognitive aging in HIV infection. *Journal of neurovirology.* 2017;23(3):492–500. [PubMed: 28321696]
23. Levine AJ, Quach A, Moore DJ, et al. Accelerated epigenetic aging in brain is associated with pre-mortem HIV-associated neurocognitive disorders. *Journal of neurovirology.* 2016;22(3):366–375. [PubMed: 26689571]
24. Gross AM, Jaeger PA, Kreisberg JF, et al. Methylome-wide Analysis of Chronic HIV Infection Reveals Five-Year Increase in Biological Age and Epigenetic Targeting of HLA. *Molecular cell.* 2016;62(2):157–168. [PubMed: 27105112]
25. Cohen RA, Harezlak J, Schifitto G, et al. Effects of nadir CD4 count and duration of human immunodeficiency virus infection on brain volumes in the highly active antiretroviral therapy era. *Journal of neurovirology.* 2010;16(1):25–32. [PubMed: 20113183]
26. Ellis RJ, Badiee J, Vaida F, et al. CD4 nadir is a predictor of HIV neurocognitive impairment in the era of combination antiretroviral therapy. *AIDS (London, England).* 2011;25(14):1747–1751.

27. Valcour V, Yee P, Williams AE, et al. Lowest ever CD4 lymphocyte count (CD4 nadir) as a predictor of current cognitive and neurological status in human immunodeficiency virus type 1 infection—The Hawaii Aging with HIV Cohort. *Journal of neurovirology*. 2006;12(5):387–391. [PubMed: 17065131]
28. Kallianpur AR, Wang Q, Jia P, et al. Anemia and Red Blood Cell Indices Predict HIV-Associated Neurocognitive Impairment in the Highly Active Antiretroviral Therapy Era. *The Journal of infectious diseases*. 2016;213(7):1065–1073. [PubMed: 26690344]
29. Mulligan K, Grunfeld C, Tai VW, et al. Hyperlipidemia and insulin resistance are induced by protease inhibitors independent of changes in body composition in patients with HIV infection. *J Acquir Immune Defic Syndr*. 2000;23(1):35–43. [PubMed: 10708054]
30. Valcour VG, Shikuma CM, Shiramizu BT, et al. Diabetes, insulin resistance, and dementia among HIV-1-infected patients. *J Acquir Immune Defic Syndr*. 2005;38(1):31–36. [PubMed: 15608521]
31. Foley J, Ettenhofer M, Wright MJ, et al. Neurocognitive functioning in HIV-1 infection: effects of cerebrovascular risk factors and age. *Clin Neuropsychol*. 2010;24(2):265–285. [PubMed: 20162495]
32. Frazer KM, Manly JJ, Downey G, Hart CL. Assessing cognitive functioning in individuals with cocaine use disorder. *J Clin Exp Neuropsychol*. 2018;40(6):619–632. [PubMed: 29226762]
33. Heaton RK, Franklin DR Jr., Deutsch R, et al. Neurocognitive change in the era of HIV combination antiretroviral therapy: the longitudinal CHARTER study. *Clinical infectious diseases : an official publication of the Infectious Diseases Society of America*. 2015;60(3):473–480. [PubMed: 25362201]
34. Walker KA, Brown GG. HIV-associated executive dysfunction in the era of modern antiretroviral therapy: A systematic review and meta-analysis. *J Clin Exp Neuropsychol*. 2018;40(4):357–376. [PubMed: 28689493]
35. Moore DJ, Masliah E, Rippeth JD, et al. Cortical and subcortical neurodegeneration is associated with HIV neurocognitive impairment. *AIDS (London, England)*. 2006;20(6):879–887.

### A. CHARTER: Final CFA Structure




### B. NNTC: Final CFA Structure



**Figure 1. Final confirmatory factor analysis for CHARTER (A) and NNTC (B).** Standardized factor loadings are presented. As detailed in the tables, this current model has satisfactory fit per multiple indices of overall model fit for both studies. Abbreviations for neuropsychological tests above are HVLT-R = Hopkins Verbal Learning Test-Revised, BVMT-R = Brief Visuospatial Memory Test-Revised, WMS-III = Wechsler Memory Scale, Third edition, PASAT = Paced Auditory Serial Addition Test, WAIS-III = Wechsler Adult Intelligence Scale – Third edition.





**Figure 2. CEF average T-score and DDS distribution, and comparisons with Frascati and GDS.** (A) Frequency distributions of CEF average T-scores in both NNTC and CHARTER reveal a good fit to a Gaussian distribution. (B) Frequency distributions of CEF DDS, with the majority for both NNTC and CHARTER having values between 0.0 and 0.2. (C) CEF average T-scores compared to Frascati diagnosis for NNTC and CHARTER. Red lines indicate median and interquartile range. One-way ANOVA for both revealed significance ( $p < 0.001$ ). Tukey’s multiple comparison tests were  $p < 0.0001$  between all conditions except ANI vs. MND, which for NNTC  $p = 0.0001$ , and CHARTER  $p = 0.0005$ . (D) CEF DDS compared to Frascati diagnosis for NNTC and CHARTER. Red lines indicate median and interquartile range. The nonparametric Kruskal-Wallis test was used given the distribution of



the data, and revealed significance ( $p < 0.0001$ ) for both. Dunn's multiple comparison tests were  $p < 0.0001$  between all conditions except ANI vs. MND, which for NNTC  $p = 0.0002$ , and CHARTER  $p = 0.0147$ , and for CHARTER only ANI vs HAD  $p = 0.0001$ , and MND vs HAD  $p = 0.0361$ . (E) ROC curves for NNTC and CHARTER, comparing GDS with the CEF average T-scores and DDS to diagnose impairment (using the Frascati criteria) for NNTC, CHARTER, and the combined cohorts. The area under the curve (auc) is indicated. (F). Frequency distribution of CEF average T-scores and DDS in unimpaired subjects from the combined NNTC and CHARTER cohorts. For the average T-scores (left) the cut-off at 1.5 SD below the mean is indicated, and for DDS (right) the cut-off at 0.5 is indicated.

**Table 1.**

Demographics and t-test comparisons between common variables in CHARTER and NNTC subsamples

	<b>CHARTER (n = 1,222)</b>			<b>NNTC (n = 798)</b>			<i>t</i>	<i>df</i>
	<i>M</i>	<i>SD</i>	<i>n</i>	<i>M</i>	<i>SD</i>	<i>n</i>		
Age	43.0	8.72	1,222	45.6	9.81	798	-6.12*	1,561*
Years of education	12.7	2.59	1,222	12.7	2.90	798	.31	1,568
Estimated duration (years) of HIV	9.8	6.32	1,194	22.3	8.00	752	-36.25*	1,328*
Beck Depression Inventory-II (BDI-II) total score	13.7	10.74	1,211	11.8	10.02	258	2.60*	1,467*
Nadir CD4 (cells/ $\mu$ L; with square-root transformation)	12.8	7.06	1,214	9.2	7.12	282	7.68*	1,494*
Current CD4 (cells/ $\mu$ L; with square-root transformation)	20.4	6.78	1,204	14.5	7.53	744	17.43*	1,450*
Total blood count hemoglobin (g/dL)	14.0	1.57	1,209	13.4	1.90	736	7.28*	1,334*

*M* = Mean, *SD* = standard deviation, *n* = sample size, *t* = t-test value, and *df* = degrees of freedom.

= Equal variances not assumed (Levene's test for Equality of Variances,  $p < 0.05$ ).

\* =  $p < .05$ .

Please note that there were a high number of missing values for BDI-II total score and nadir CD4 in NNTC.

**Table 2.**

Demographics and chi-square comparisons between common variables in CHARTER and NNTC subsamples.

	CHARTER Cell counts	NNTC Cell counts	$\chi^2$	df
Male	949 (77.7%)	643 (80.6%)	2.46	1
Female	273 (22.3%)	155 (19.4%)		
Caucasian/White	515 (42.1%)	350 (43.9%)	97.45*	3*
African American/Black	565 (46.2%)	242 (30.3%)		
Hispanic	109 (8.9%)	184 (23.1%)		
Other	33 (2.7%)	22 (2.8%)		
History of methamphetamine abuse/dependence present	202 (16.7%)	41 (7.9%)	22.78*	1*
History of methamphetamine abuse/dependence absent	1010 (83.3%)	475 (92%)		
History of cocaine abuse/dependence present	497 (41.0%)	84 (16.3%)	98.74*	1*
History of cocaine abuse/dependence absent	715 (59.0%)	431 (83.7%)		
History of alcohol abuse/dependence present	655 (54.0%)	89 (17.3%)	197.86*	1*
History of alcohol abuse/dependence absent	557 (46.0%)	424 (82.7%)		
History of viral hepatitis present	557 (45.8%)	178 (33.9%)	21.29*	1*
History of viral hepatitis absent	659 (54.2%)	347 (66.1%)		
History of hypertension present	513 (42.2%)	125 (23.7%)	54.39*	1*
History of hypertension absent	703 (57.8%)	403 (76.3%)		
History of hyperlipidemia present	362 (29.6%)	86 (16.3%)	34.09*	1*
History of hyperlipidemia absent	859 (70.4%)	440 (83.7%)		
History of diabetes present	132 (10.8%)	67 (12.7%)	1.35	1
History of diabetes absent	1,089 (89.2%)	459 (87.3%)		
No current ARV treatment	168 (13.8%)	95 (12.0%)	169.69*	3*
ARV naive	196 (16.1%)	0 (0%)		
Non-cART	89 (7.3%)	129 (16.3%)		
cART	767 (62.9%)	566 (71.6%)		

$\chi^2$  = chi-square value, df = degrees of freedom, and

\* =  $p < .05$ .

**Table 3.**

Neuropsychological tests shared across CHARTER and NNTC cohorts, by domains as specified in previous CHARTER/NNTC literature.

Cognitive Domain	Test
<b>Premorbid estimate</b>	Wide Range Achievement Test-3 (WRAT-3) Word Reading subtest <sup>1</sup>
<b>Speed of information processing</b>	Wechsler Adult Intelligence Scale-3 <sup>rd</sup> ed. (WAIS-III) Digit Symbol <sup>2</sup> WAIS-III Symbol Search <sup>2</sup> Trail Making Test, Part A <sup>3</sup>
<b>Verbal Fluency</b>	Controlled Oral Word Association Test <sup>3</sup> Animals <sup>3</sup>
<b>Learning</b>	Hopkins Verbal Learning Test-Revised – Trials 1–3 <sup>4,5</sup> Brief Visuospatial Memory Test-Revised – Trials 1–3 <sup>5,6</sup>
<b>Memory</b>	Hopkins Verbal Learning Test-Revised – Delayed recall <sup>4,5</sup> Brief Visuospatial Memory Test-Revised – Delayed recall <sup>5,6</sup>
<b>Abstraction/Executive functioning</b>	Wisconsin Card Sorting Test-64 item, perseverative responses <sup>3,5</sup> Trail Making Test, Part B <sup>3</sup>
<b>Attention/Working Memory</b>	WAIS-III Letter-Number Sequencing <sup>2</sup> Paced Auditory Serial Addition Task (first channel only) <sup>7</sup>
<b>Motor</b>	Grooved Pegboard Test (dominant and non-dominant hands) <sup>3</sup>

<sup>1</sup>Wilkinson GS. *Wide Range Achievement Test 3*. Wilmington, DE: Wide Range, Inc.; 1993.

<sup>2</sup>Wechsler D. *Wechsler Adult Intelligence Scale – Third Edition*. San Antonio, TX: Psychological Corporation; 1997.

<sup>3</sup>Heaton RK, Miller, W., Taylor, M. J., Grant I. *Revised comprehensive norms for an expanded Halstead-Reitan battery: Demographically adjusted neuropsychological norms for African American and Caucasian adults, professional manual*. Lutz, FL: Psychological Assessment Resources, Inc.; 2004.

<sup>4</sup>Benedict R, Schretlen, D, Groninger, L, & Brandt, J Hopkins Verbal Learning Test-Revised: Normative data and analysis of inter-form and test-retest reliability. *The Clinical Neuropsychologist*. 1998;12:43–55.

<sup>5</sup>Norman MA, Moore DJ, Taylor M, et al. Demographically corrected norms for African Americans and Caucasians on the Hopkins Verbal Learning Test–Revised, Brief Visuospatial Memory Test–Revised, Stroop Color and Word Test, and Wisconsin Card Sorting Test 64-Card Version. *Journal of Clinical and Experimental Neuropsychology*. 2011;33(7):793–804.

<sup>6</sup>Benedict R. *Brief Visuospatial Memory Test - Revised*. Odessa, Florida: Psychological Assessment Resources, Inc.; 1997.

<sup>7</sup>Diehr MC, Cherner, M., Wolfson, T.J., Miller, S.W., Grant, I., & Heaton, R.K. . The 50 and 100-Item Short Forms of the Paced Auditory Serial Addition Task (PASAT): Demographically Corrected Norms and Comparisons with the Full PASAT in Normal and Clinical Samples. *Journal of Clinical and Experimental Neuropsychology*;25:571–585.